Monitoring temporal changes in SARS-CoV-2 spike antibody levels and variant-specific risk for infection, Dominican Republic, March 2021–August 2022
Fecha
2023Autor
Nilles, Eric J.
de St. Aubin, Michael
Dumas, Devan
Duke, William
Etienne, Marie Caroline
Abdalla, Gabriela
Jarolim, Petr
Oasan, Timothy
Garnier, Salome
Iihoshi, Naomi
Lopez, Beatriz
de la Cruz, Lucia
Cornelio Puello, Yosanly
Baldwin, Margaret
Roberts, Kathryn W.
Peña, Farah
Durski, Kara
Sanchez, Isaac Miguel
Gunter, Sarah M.
Kneubehl, Alexander R.
Murray, Kristy O.
Lino, Allison
Strobel, Sarah
Baez, Amado Alejandro
Lau, Colleen L.
Kucharski, Adam
Kucharski, Adam
Zielinski Gutiérrez, Emily
Skewes-Ramm, Ronald
Vasquez, Marietta
Then Paulino, Cecilia
Metadatos
Mostrar el registro completo del ítemResumen
To assess changes in SARS-CoV-2 spike binding antibody
prevalence in the Dominican Republic and implications
for immunologic protection against variants of
concern, we prospectively enrolled 2,300 patients with
undifferentiated febrile illnesses in a study during March
2021–August 2022. We tested serum samples for spike
antibodies and tested nasopharyngeal samples for acute
SARS-CoV-2 infection using a reverse transcription PCR
nucleic acid amplification test. Geometric mean spike antibody
titers increased from 6.6 (95% CI 5.1–8.7) binding
antibody units (BAU)/mL during March–June 2021 to
1,332 (95% CI 1,055–1,682) BAU/mL during May–
August 2022. Multivariable binomial odds ratios for acute
infection were 0.55 (95% CI 0.40–0.74), 0.38 (95% CI
0.27–0.55), and 0.27 (95% CI 0.18–0.40) for the second,
third, and fourth versus the first anti-spike quartile; findings
were similar by viral strain. Combining serologic and
virologic screening might enable monitoring of discrete
population immunologic markers and their implications
for emergent variant transmission
Colecciones
El ítem tiene asociados los siguientes ficheros de licencia: